Similar Papers

Paper Title
Journal
Date
Author
Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Charles Erlichman ... Biserka Mitrovski
Cancer chemotherapy and pharmacology | VOL. 34
Charles Erlichman, et. al.Charles Erlichman ... Biserka Mitrovski
01 Jan 1993
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
S J Clarke ... J Hanwell
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | VOL. 14
S J Clarke, et. al.S J Clarke ... J Hanwell
01 May 1996
Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]- N6-methyl-2, 6-diaminobenz[ cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity
Josie Pressacco ... Charles Erlichman
Biochemical Pharmacology | VOL. 50
Josie Pressacco, et. al.Josie Pressacco ... Charles Erlichman
01 Jun 1995
Mechanisms of resistance to N-[5-[ N-(3, 4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)- N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line
Kun Lu ... Youcef M Rustum
Biochemical Pharmacology | VOL. 50
Kun Lu, et. al.Kun Lu ... Youcef M Rustum
01 Jul 1995
View more papers

More From: Cancer Chemotherapy and Pharmacology

Paper Title
Journal
Date
Author
Retraction Note: Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma.
Hui Zhang ... Chao Shang
Cancer chemotherapy and pharmacology | VOL. 95
Hui Zhang, et. al.Hui Zhang ... Chao Shang
03 Feb 2025
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1).
Masaki Ri ... Hirokazu Nagai
Cancer chemotherapy and pharmacology | VOL. 95
Masaki Ri, et. al.Masaki Ri ... Hirokazu Nagai
24 Jan 2025
HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
Kunihiko Funaishi ... Noboru Hattori
Cancer Chemotherapy and Pharmacology | VOL. 95
Kunihiko Funaishi, et. al.Kunihiko Funaishi ... Noboru Hattori
24 Jan 2025
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).
Anuradha Krishnamurthy ... Liza C Villaruz
Cancer chemotherapy and pharmacology | VOL. 95
Anuradha Krishnamurthy, et. al.Anuradha Krishnamurthy ... Liza C Villaruz
22 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.